{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:48:24Z","timestamp":1775674104953,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.nrleng.2026.501912","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:37:34Z","timestamp":1775669854000},"page":"501912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs"],"prefix":"10.1016","volume":"41","author":[{"given":"E.","family":"Cort\u00e9s-Vicente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Juntas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rodr\u00edguez de Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guerrero Sola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2026.501912_bib0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0200","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.nrleng.2026.501912_bib0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nrleng.2026.501912_bib0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis \u2013 results from population-based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nrleng.2026.501912_bib0215","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrleng.2026.501912_bib0220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.nrleng.2026.501912_bib0225","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1212\/CON.0000000000000800","article-title":"Myasthenia gravis and congenital myasthenic syndromes","volume":"25","author":"Ciafaloni","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.nrleng.2026.501912_bib0230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrleng.2026.501912_bib0235","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-010-5549-9","article-title":"Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"Winter","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/00207454.2013.853664","volume":"124","author":"Ariatti","year":"2014","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.nrleng.2026.501912_bib0245","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0250","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0255","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.nrleng.2026.501912_bib0260","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","article-title":"Frequency and clinical features of treatment-refractory myasthenia gravis","volume":"267","author":"Rath","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0265","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0270","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.3390\/jcm11216394","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.nrleng.2026.501912_bib0275","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12883-022-02981-y","article-title":"Myasthenia gravis \u2013 a retrospective analysis of e-mail inquiries made to a patient organisation and specialized center to uncover unmet needs from patients and caregivers","volume":"22","author":"Stein","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0280","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp.54.9.846","article-title":"First description of myasthenia gravis in Spain","volume":"54","author":"Morales","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrleng.2026.501912_bib0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.33588\/rn.7602.2021201","volume":"76","author":"Garc\u00eda-Est\u00e9vez","year":"2023","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","article-title":"Prevalence of myasthenia gravis in the Catalan county of Osona","volume":"32","author":"Aragon\u00e8s","year":"2017","journal-title":"Neurologia"},{"key":"10.1016\/j.nrleng.2026.501912_bib0295","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ncl.2020.03.005","volume":"38","author":"Nguyen","year":"2020","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nrleng.2026.501912_bib0300","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.501912_bib0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.501912_bib0310","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","article-title":"Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis","volume":"19","author":"Salari","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.nrleng.2026.501912_bib0315","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221150327","volume":"16","author":"Mahic","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrleng.2026.501912_bib0320","article-title":"Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain)","author":"Garc\u00eda Est\u00e9vez","year":"2022","journal-title":"Neurologia (Engl Ed)"},{"key":"10.1016\/j.nrleng.2026.501912_bib0325","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0330","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.501912_bib0335","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.asjsur.2020.12.013","volume":"44","author":"Al-Bulushi","year":"2021","journal-title":"Asian J Surg"},{"key":"10.1016\/j.nrleng.2026.501912_bib0340","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.501912_bib0345","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","volume":"268","author":"Lotan","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0355","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mus.23508","article-title":"A retrospective study of complications of therapeutic plasma exchange in myasthenia","volume":"47","author":"Guptill","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2026.501912_bib0360","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","article-title":"Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis","volume":"267","author":"Gomez-Figueroa","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2026.501912_bib0365","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jocn.2014.03.019","volume":"21","author":"Nagappa","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nrleng.2026.501912_bib0370","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J Neurol"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082600026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082600026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:38:09Z","timestamp":1775669889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217358082600026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S217358082600026X"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.501912","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.501912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501912"}}